Xocova：證實了 Omicron 菌株的效果！
-口服藥物Xocova的最終臨床試驗-
鹽野木製藥：
9月28日，
Zokoba，一種正在開發的新型冠狀病毒藥物
最後階段的臨床試驗證實了 Omicron 菌株的功效。
新冠
喝藥“佐科巴”
關於“Omicron株特有的發熱、流鼻涕等5種症狀消失的時間”
“我們能夠確認將時間縮短 24 小時的效果，”他說。
未來，我們將盡快進行進一步的數據分析以供審批。
(朝日新聞數碼)-Yahoo! 新聞
https://news.yahoo.co.jp/articles/2df2006fa6298f654efffd652aaee752183d4f8c
Xocova : Effet confirmé avec la souche Omicron !
-Essai clinique final du médicament oral Xocova-
Shionogi pharmaceutique :
28 septembre,
Zokoba, un nouveau médicament corona en cours de développement
Un essai clinique de phase finale a confirmé l’efficacité avec la souche Omicron.
nouvelle couronne
Médicament à boire “Zokoba”
À propos de “Il est temps de faire disparaître cinq symptômes tels que la fièvre et l’écoulement nasal caractéristiques de la souche Omicron”
“Nous avons pu confirmer l’effet du raccourcissement du délai de 24 heures”, a-t-il déclaré.
À l’avenir, nous procéderons à une analyse plus approfondie des données pour approbation dès que possible.
(Asahi Shimbun Digital) – Yahoo Actualités
Xocova: Wirkung mit Omicron-Stamm bestätigt!
-Abschließende klinische Studie zum oralen Medikament Xocova-
Shionogi Pharma:
28. September,
Zokoba, ein neues Corona-Medikament in der Entwicklung
Eine klinische Studie im Endstadium bestätigte die Wirksamkeit des Omicron-Stammes.
neue Korona
Trinkmedizin “Zokoba”
Über “Zeit, um fünf Symptome wie Fieber und laufende Nase zu beseitigen, die für den Omicron-Stamm charakteristisch sind”
„Wir konnten den Effekt der Zeitverkürzung um 24 Stunden bestätigen“, sagte er.
In Zukunft werden wir so schnell wie möglich mit weiteren Datenanalysen für die Zulassung fortfahren.
(Asahi Shimbun Digital) – Yahoo!-Nachrichten
Shionogi oral coronavirus drug found effective in clinical trial
NHK WORLD-JAPAN News
Japanese pharmaceutical company
Shionogi says its orally administered coronavirus treatment drug has been found to improve symptoms in the final stage of its clinical trial.
Shionogi on Wednesday
announced the results of the third and final phase of its clinical trial on the oral drug Xocova.
Coronavirus patients aged 12 through 69 with mild to moderate symptoms
were eligible to take part in the trial. Some 1,800 patients participated.
It was conducted from February through mid-July of this year.
The patients were divided into two groups.
One group was given Xocova
once a day for five days, while the other was given a placebo.
Neither the patients nor doctors knew which group was being administered the drug.
The patients in the group that was given the drug lost all five major symptoms
—
cough,
sore throat,
stuffy or runny nose,
tiredness and fever
—
in about seven days.
This improvement came about 24 hours earlier than in those in the placebo group.
In addition,
the amount of the virus in the bodies of the patients given the drug was found to have decreased significantly on day four of the study.
The patients suffered no serious side effects.
Shionogi applied to Japan’s health ministry
earlier in the year for emergency authorization of this first-ever oral drug that can be administered to people who are not at risk of serious illness.
A ministry council decided in July
to continue deliberating the application, citing a lack of data to suggest efficacy.
The company plans to submit its newly acquired data to the ministry and other relevant bodies.